Revising the definition of Alzheimer's disease: a new lexicon.

By Bruno Dubois, H. Feldman, C. Jacova, Jeffrey L. Cummings, Steven DeKosky, P. Barberger‐Gateau, A. Delacourte, Giovanni B. Frisoni, Nick C Fox, D. Galasko and 14 more. Lancet Neurology, 2010

1,937 citations recorded by the source corpus.

Subfields: Pharmacology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/05f87cd51d602a643bf8f0ce8468ef827dda6a1b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, neutral): “While differences remain, IWG 2016 and the NIA research framework are aligned on the key issue that the combination of an abnormal Ab and tau biomarker constitutes AD regardless of cognitive symptoms, and thus AD is a biologically defined entity throughout its continuum.”
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021 (2021, neutral): “Preclinical AD, as the earliest stage in the AD continuum, comprises a long asymptomatic phase, in which individuals have evidence of AD pathology but no evidence of cognitive or functional decline, and their daily life is unaffected (8) (Figure 1).”
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011, background): “To facilitate the possibility of future presymptomatic/preclinical treatment of AD, our working group, as well as the other two groups, felt it was important to define AD as encompassing the underlying pathophysiological disease process, as opposed to having “AD” connote only the clinical stages of ”
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease (2014, neutral): “The International Working Group (IWG) proposed (1) the asymptomatic at-risk stage of AD (AD pathology evidenced by biomarkers and no symptoms), (2) prodromal AD (episodic memory deficit with impaired cued recall that can be isolated or in association with other cognitive changes and biomarker eviden”
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, background): “The international working group (IWG) has defined two different preclinical states: the presymptomatic and the asymptomatic at risk state [8].”
Introduction to Revised Criteria for the Diagnosis of Alzheimer’s Disease: National Institute on Aging and the Alzheimer Association Workgroups (2011, background): “[17] Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Bar-”
Impact of multiple pathologies on the threshold for clinically overt dementia (2017, background): “Lack of a concise and sensitive cognitive biomarker of AD has led to the widespread use of ancillary testing, particularly CSF and imaging markers, which have been codified into a number of recent diagnostic guidelines [34, 52].”